Figure 2.
Kaplan-Meier estimates of OS and PFS among patients treated with regorafenib combined with PD-1 inhibitors. OS, overall survival; PFS, progression-free survival; PD-1, programmed cell death protein 1.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.